Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • TA119
  • Published: 
Download guidance (PDF)

Appendix B. Sources of evidence considered by the Committee

A. The following manufacturer provided a submission for this appraisal:

  • Schering Health Care Limited

B. The Evidence Review Group report for this appraisal was prepared by the Centre for Health Economics, University of York (Walker S, Palmer S) and the NHS Northern and Yorkshire Regional Drug and Therapeutics Centre (Erhorn S, Brent S, Dyker A et al.), August 2006. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.

C. The following individuals were selected from clinical specialist and patient advocate nominations from the professional/specialist and patient/carer groups. They gave their expert personal view on fludarabine by providing written and oral evidence to the Committee. They were also invited to comment on the appraisal consultation document (ACD).

  • Professor Terry Hamblin, Professor of Immunohaematology, nominated by the Leukaemia Research Fund as a clinical specialist

  • Dr Andrew Pettitt, Reader and Consultant Haematologist, nominated by the British Committee for Standards in Haematology as a clinical specialist

  • Jane Barnard, patient member, nominated by the Chronic Lymphocytic Leukemia Support Association as a patient expert

  • Dr Howard Pearce, chairman of and nominated by the Chronic Lymphocytic Leukemia Support Association as a patient expert.